CJC-1295 with DAC vs Oxandrolone
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC-1295 with DAC and Oxandrolone work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 with DAC Oxandrolone
Weight 3,647.28 Da 306.44 Da
Half-life 6-8 days ~9-10 hours
Chain 30 amino acids —
Type GHRH analog with DAC 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Oxandrolone
01 Promotes lean muscle mass gains with minimal water retention
02 Supports recovery of lost body weight following surgery, trauma, or chronic illness
03 Reduces bone pain associated with osteoporosis and improves bone mineral density
04 Does not aromatize to estrogen, avoiding estrogen-related side effects
05 Well-studied safety profile in women, children, and burn patients
06 Enhances nitrogen retention and protein synthesis during caloric deficit
07 Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
08 Lower androgenic potency compared to most oral anabolic steroids
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Oxandrolone
20-50 mg/day (male), 5-20 mg/day (female) / Split into 2 doses daily (morning and evening)
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Oxandrolone
HDL cholesterol suppression (dose-dependent, most significant lipid effect)
LDL cholesterol elevation
Mild hepatic stress (elevated liver enzymes ALT/AST)
Suppression of endogenous testosterone production
Mild headaches
Nausea or gastrointestinal discomfort
Changes in libido (increase or decrease depending on hormonal context)
Oily skin and mild acne
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Nephrosis or nephrotic phase of nephritis
Hypercalcemia
Severe hepatic dysfunction or active liver disease
Hypersensitivity to oxandrolone or any formulation component
Research Evidence
CJC-1295 with DAC Oxandrolone
Status Well Studied Well Studied
References 4 studies 5 studies
Latest 2025 September 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.